Exelixis Stock News

Huntington National Bank raised its stake in shares of Exelixis, Inc. (NASDAQ:EXEL) by 156.4% in the 3rd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 1,433 shares of the biotechnology companys stock after acquiring an additional 874 shares during the period. Huntington National Banks []

Exelixis, Inc. (NASDAQ:EXEL) EVP Peter Lamb sold 47,500 shares of Exelixis stock in a transaction that occurred on Wednesday, December 15th. The shares were sold at an average price of $17.44, for a total value of $828,400.00. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. Peter Lamb []

Tandem Capital Management Corp ADV lessened its stake in Exelixis, Inc. (NASDAQ:EXEL) by 37.4% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 9,650 shares of the biotechnology company’s stock after selling 5,770 shares during the quarter. Tandem Capital Management Corp […]

ALAMEDA, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL) today announced that accomplished technology executive Jacqueline (Jacky) Wright has been elected to the companys Board of Directors. Ms. Wrights appointment took effect on December 16, 2021. Ms. Wright has decades of technology experience and is widely recognized for her expertise in digital transformation, both in the public and private sectors. She currently serves as Corporate Vice President & Chief Digital Officer, U.S.

ERYTECH Pharma (NASDAQ:ERYP) and Exelixis (NASDAQ:EXEL) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, dividends, earnings, analyst recommendations, profitability, institutional ownership and risk. Profitability This table compares ERYTECH Pharma and Exelixis’ net margins, return on equity and return on assets. […]

Exelixis (EXEL) begins the dose-escalation stage of its study evaluating XL092 in combination with immuno-oncology therapies in patients with advanced solid tumors.

Exelixis (EXEL) begins the dose-escalation stage of its study evaluating XL092 in combination with immuno-oncology therapies in patients with advanced solid tumors.

Stephens Investment Management Group LLC lifted its holdings in Exelixis, Inc. (NASDAQ:EXEL) by 17.4% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 3,432,147 shares of the biotechnology companys stock after buying an additional 508,967 shares during the period. []

– STELLAR-002 is second trial to evaluate XL092, a next-generation tyrosine kinase inhibitor, in advanced cancers – ALAMEDA, Calif. --(BUSINESS WIRE)--Dec. 15, 2021-- Exelixis, Inc. (Nasdaq: EXEL) today announced initiation of the dose-escalation stage of STELLAR-002, a phase 1b trial evaluating

But both have been crashing so far in 2021.

But both have been crashing so far in 2021.

Sales are climbing at these biotech companies -- and more potential products are on the horizon.

A small investment can go a long way with this mix of growth, income, and value stocks.

Sales are climbing at these biotech companies -- and more potential products are on the horizon.

A small investment can go a long way with this mix of growth, income, and value stocks.